Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated Viruses

9 Jan 2009

Abstract excerpt

Recombinant adeno-associated viruses (AAVs) have unique gene-transfer properties that speak to their potential as carriers for gene therapy or vaccine applications. However, the presence of neutralizing antibodies to AAV as a result of previous exposure can significantly limit effective gene transfer. In this study, we obtained 888 human serum samples from healthy volunteers in 10 countries around the world....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19133809
DOI: 10.1086/595830

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated VirusesPMID 19133809Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypesSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)Semantic proximity Read ↗

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsSemantic proximity Read ↗

Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene TransferSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disordersSemantic proximity Read ↗

Challenges in Humoral Immune Response to Adeno-Associated Viruses DeterminationSemantic proximity Read ↗

Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donorsSemantic proximity Read ↗

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.